MustGrow Launches $2M LIFE Financing to Support Commercial Momentum

MustGrow Biologics (OTCQB: MGROF) announced a non-brokered LIFE offering targeting up to $2 million in gross proceeds, strengthening its balance sheet as the company advances commercialization efforts in biological crop protection.

The financing is structured to provide near-term capital while maintaining flexibility, allowing MustGrow to fund operations and growth initiatives without relying on a traditional prospectus-based raise. Units issued in the offering include common shares and warrants, giving investors participation in both the current valuation and potential future upside.

Capital to Support Execution

Management expects to use proceeds primarily to support:

• Commercial rollout and sales expansion of its biological solutions
• Working capital and operational needs as adoption scales
• Strategic and regulatory initiatives tied to product advancement

By raising capital at this stage, MustGrow aims to extend its runway through a key execution phase as it transitions further toward revenue generation.

Why the Structure Matters

The LIFE exemption allows the company to raise capital efficiently and broaden participation among retail investors, while the non-brokered format helps reduce transaction costs and potential dilution. The inclusion of warrants is designed to align longer-term investor interest with the company’s execution progress.

Investor Perspective

For investors, the offering highlights a balance between capital discipline and growth optionality. While dilution risk remains typical for early-stage ag-biotech companies, the financing provides MustGrow with the resources needed to pursue near-term commercial milestones in a sector benefiting from sustainability and regulatory tailwinds.

Bottom Line

This financing is positioned as a bridge to execution, reinforcing MustGrow’s financial footing as it works to convert product development into commercial traction. Investor attention will likely focus on how efficiently capital is deployed and whether upcoming sales and partnership milestones validate the growth strategy.